3 Reasons Why Gilead Sciences Stock Is a Buy Now

Gilead Sciences (NASDAQ: GILD) is a biotech behemoth, but its shares have fallen on tough times because hepatitis C sales are slipping. While headwinds in hepatitis C remain, the company's recent push into cancer treatment, best-in-class operating metrics, and cheap valuation make it a stock worth owning.

Make no mistake -- Gilead Sciences' decision to leapfrog to the forefront of oncology research by acquiring Kite Pharma is a big reason why this company's stock should be in your portfolio.

IMAGE SOURCE: GETTY IMAGES.

Continue reading


Source: Fool.com